Skip to content
HowShorted

Anika Therapeutics Inc. short interest in 2021

In 2021, Anika Therapeutics Inc.'s disclosed short interest ran from 10.46% of shares outstanding on 15 Jan 2021 to 6.78% on 31 Dec 2021, a change of -3.68 percentage points. The year's high was 11.88% on 15 Apr 2021 and its low 5.24% on 15 Nov 2021, averaging 8.92% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.57 days on 28 May 2021. Full history: Anika Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Anika Therapeutics Inc. in 2021

2021 in figures

Start of year
10.46% (15 Jan 2021)
End of year
6.78% (31 Dec 2021)
Change
-3.68 pp
High
11.88% (15 Apr 2021)
Low
5.24% (15 Nov 2021)
Average
8.92%
Highest days to cover
27.57 (28 May 2021)
SEC filings marked
8

Every report in 2021

Anika Therapeutics Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202110.46%12.90
29 Jan 202110.28%17.41
12 Feb 20219.84%16.05
26 Feb 20219.11%8.14
15 Mar 20219.40%11.40results (8-K), 10-K filed
31 Mar 202110.10%6.88
15 Apr 202111.88%13.49
30 Apr 202111.51%18.43
14 May 202111.28%16.85results (8-K), 10-Q filed
28 May 202111.13%27.57
15 Jun 202110.28%11.30
30 Jun 20219.41%10.46
15 Jul 20219.15%18.42
30 Jul 20218.98%25.32
13 Aug 20218.73%24.00results (8-K), 10-Q filed
31 Aug 20218.35%16.82
15 Sep 20218.37%17.22
30 Sep 20217.38%11.85
15 Oct 20217.41%16.83
29 Oct 20217.38%20.17
15 Nov 20215.24%9.99results (8-K), 10-Q filed
30 Nov 20215.60%9.72
15 Dec 20215.99%11.76
31 Dec 20216.78%8.18

See also: Anika Therapeutics Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.